Cycloastragenol Anti-Diabetic Effects in Zucker Diabetic Fatty Rats

A research dataset from Guangzhou University of Chinese Medicine details the therapeutic effects of cycloastragenol on Type II Diabetes mellitus in rodent models. The data likely contains results from oral glucose tolerance tests in KunMing mice and Zucker Diabetic Fatty rats over a 5-week treatment period, including measurements of plasma glucose, dyslipidemia, and organ fibrosis. The underlying molecular mechanism involving the sodium/glucose co-transporter 2 (SGLT2) was explored in HEK293 cells.

Use Cases

• Evaluating glucose-lowering effects of natural compounds based on plasma glucose and glucose tolerance test results.
• Studying the amelioration of diabetes complications based on metrics for hyperglycemia, dyslipidemia, and organ fibrosis.
• Investigating molecular mechanisms of anti-diabetic agents based on SGLT2 expression and glucose transport inhibition data.
• Comparing the efficacy of different metabolites from traditional Chinese plants based on comparative results between cycloastragenol and astragaloside IV.

Strengths

• Data is derived from controlled experimental studies in two rodent models (KunMing mice and Zucker Diabetic Fatty rats).
• The study includes a 5-week treatment period and explores molecular mechanisms in cell lines.
• Results are linked to specific clinical symptoms and a proposed molecular target (SGLT2).

Limitations

• Row count and dataset size are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred from the research paper.
• The dataset appears to be a single study's results, which may limit generalizability.

Provenance

Source

Guangzhou University of Chinese Medicine

Collection Method

Experimental data from pharmacological studies in rodent models and cell cultures.